Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PolBrom-PPCM: Prolonged Bromocriptine in Peripartum Cardiomyopathy
2021-006639-24Phase 3Terminated
- Sponsor
- National Institute of Cardiology
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bromocriptine in Peripartum cardiomyopathy (PPCM) (2 arms), sponsored by National Institute of Cardiology. Primary endpoints: Clinical effectiveness of prolonged bromocriptine treatment and Novel biomarker-based diagnostic scheme for PPCM. Started Apr 2022; status: terminated.
02
Drugs
bromocriptine
03
Conditions
Peripartum cardiomyopathy (PPCM)
Beyond the preview
Go deeper on 2021-006639-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006639-24.